An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Mardepodect (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 09 Mar 2017 Status changed from recruiting to discontinued.
- 31 Jan 2017 Planned End Date changed from 1 Sep 2017 to 1 Feb 2017.
- 31 Jan 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Feb 2017.